Ownership and insider activity for Recursion Pharmaceuticals, Inc. (RXRX): recent transactions by executives and directors. Track how corporate insiders are trading the stock.
Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering.
Price
| Price | $3.83 (closing price, November 2, 2026) |
| Market Cap | $2.3B |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $69.9M | $262.1M | $285.1M | $549.9M | $391.6M | $594.4M | $743.3M |
| Short-term Investments | 0 | 0 | $231.4M | 0 | 0 | 0 | 0 |
| Receivables | $151,000 | $156,000 | $9.1M | $2.8M | $3.1M | $49.2M | $24.6M |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $76.4M | $266.4M | $534.7M | $569.8M | $438.1M | $714.3M | $812.8M |
| Property, Plant & Equipment | $24.4M | $26.0M | $64.7M | $121.4M | $120.2M | $233.2M | $169.5M |
| Goodwill | 0 | $801,000 | $801,000 | $801,000 | $52.1M | $148.9M | $162.2M |
| Intangible Assets | 0 | $1.7M | $1.4M | $1.3M | $36.4M | $335.9M | $309.9M |
| Total Assets | $101.4M | $298.6M | $610.3M | $701.3M | $653.7M | $1.45B | $1.47B |
| Accounts Payable | $1.3M | $1.1M | $2.8M | $4.6M | $4.0M | $21.6M | $18.1M |
| Short-term Debt | $77,000 | $1.1M | $90,000 | $97,000 | $41,000 | $8.4M | $9.1M |
| Total Current Liabilities | $6.7M | $23.1M | $46.7M | $100.3M | $93.2M | $187.5M | $147.7M |
| Long-term Debt | $12.4M | $11.4M | $633,000 | $536,000 | $1.1M | $19.0M | $9.6M |
| Total Liabilities | $225.7M | $504.9M | $67.4M | $215.5M | $190.3M | $413.8M | $343.3M |
| Retained Earnings | -$126.6M | -$213.6M | -$400.1M | -$639.6M | -$967.6M | -$1.43B | -$2.08B |
| Total Equity | -$124.3M | -$206.3M | $542.9M | $485.8M | $463.4M | $1.03B | $1.13B |
| Total Debt | $16.2M | $15.7M | $11.5M | $51.0M | $50.7M | $108.5M | $78.0M |
| Net Debt | -$53.7M | -$246.5M | -$505.1M | -$498.9M | -$340.9M | -$485.9M | -$665.3M |
| Working Capital | $69.7M | $243.3M | $488.1M | $469.5M | $345.0M | $526.8M | $665.1M |
Financial Health
| Debt / Equity | 0.08 |
| Current Ratio | 5.01 |
| Piotroski F-Score | 4 |
| Altman Z-Score | 0.37 |
Profitability
| Return on Equity | -47.85% |
| Return on Invested Capital | -43.66% |
| Return on Assets | -38.93% |
| Gross Margin | 10.74% |
| Operating Margin | -725.44% |
| Net Margin | -697.13% |
Related companies: DNLI · RLAY · VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX
Explore sector: Healthcare · Biotechnology
More sections of RXRX: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks